Methotrexate Solution
FDA Label NDC 0143-9518

64 label sections · Submitted to the FDA by Hikma Pharmaceuticals Usa Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Hikma Pharmaceuticals Usa Inc. for the product Methotrexate (NDC 0143-9518). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding warning: embryo-fetal toxicity, hypersensitivity reactions, benzyl alcohol toxicity, and other serious adverse reactions, 1.1 acute lymphoblastic leukemia, 1.2 meningeal leukemia: prophylaxis and treatment, 1.3 non-hodgkin lymphoma, 1.4 osteosarcoma, 1.5 breast cancer, 1.6 squamous cell carcinoma of the head and neck, 1.7 gestational trophoblastic neoplasia, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

* Please review the disclaimer below.